Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
Effect of Age on Efficacy and Response Time of Latanoprost 0.005% in Patients With Glaucoma
1 other identifier
interventional
17
1 country
1
Brief Summary
Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We are going to study the effectiveness of Latanoprost in people of different ages, to see if it changes based on the age of the patient.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Mar 2005
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 16, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2009
CompletedResults Posted
Study results publicly available
December 10, 2012
CompletedDecember 10, 2012
November 1, 2012
4.1 years
September 16, 2005
November 9, 2012
November 9, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Pre-Treatment IOP (Intraocular Pressure)
Subjects applied topical latanoprost at bedtime for 8 weeks
At baseline (before treatment)
Post-Treatment IOP (Intraocular Pressure)
Subjects applied topical latanoprost at bedtime for 8 weeks
8 Weeks
Study Arms (1)
1
OTHERAll participants will be taking Latanoprost; This study compares efficacy within age groups.
Interventions
Eligibility Criteria
You may qualify if:
- diagnosis of open angle glaucoma,
- pseudoexfoliation glaucoma, pigmentary glaucoma or ocular hypertension in one or both eyes;
- IOP above their target pressure as determined by a glaucoma specialist;
- willingness to participate in the study.
You may not qualify if:
- hypersensitivity to any of the components of the treatment medication;
- previous use of topical prostaglandins;
- documented ocular infection or intraocular inflammation within the past year;
- previous filtering surgery or complicated cataract surgery;
- active corneal disease;
- presence of cystoid macular edema;
- laser trabeculoplasty or any other ocular laser procedure within the past three months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
- Pfizercollaborator
Study Sites (1)
Yale Eye Center
New Haven, Connecticut, 06510, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Bruce Shields, MD
- Organization
- Principal Investigator
Study Officials
- PRINCIPAL INVESTIGATOR
Bruce Shields, MD
Yale University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 16, 2005
First Posted
September 22, 2005
Study Start
March 1, 2005
Primary Completion
April 1, 2009
Study Completion
April 1, 2009
Last Updated
December 10, 2012
Results First Posted
December 10, 2012
Record last verified: 2012-11